Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 121 Richmond Street West , Penthouse Suite, 1300 TORONTO ON M5H 2K1 |
Tel: | N/A |
Website: | https://www.psyence.com |
IR: | See website |
Key People | ||
Jody Aufrichtig Executive Chairman of the Board | Adri Botha Interim Chief Financial Officer |
Business Overview |
Psyence Group Inc. is a Canada-based life science biotechnology company with a focus on natural psychedelics. The Company is focused on the research, cultivation and production of psychedelics and nature-based compounds to treat psychological trauma in the context of palliative care and in support of mental wellness. It cultivates natural psilocybin mushrooms (Psilocybe Cubensis) at its federally licensed ISO22000 facility in Southern Africa. The Company's divisions include Psyence Production, Psyence Therapeutics and Psyence Function. Psyence Therapeutics develops natural psilocybin products, medicinal formulations and treatment protocols to treat mental health disorders in a clinical environment. Psyence Production operates federally licensed ISO22000 certified psilocybin cultivation and production facilities in the world. Psyence Function is focused on the development, distribution and sale of over-the-counter functional mushroom nutraceutical products. |
Financial Overview |
For the nine months ended 31 December 2023, Psyence Group Inc revenues decreased from C$6K to C$0K. Net loss applicable to common stockholders decreased 29% to C$2.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Sales and marketing decrease of 92% to C$21K (expense), General and administrative decrease of 24% to C$443K (expense). |
Employees: | 21 as of Dec 31, 2005 |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $2.53M as of Dec 31, 2023 |
Annual revenue (TTM): | $-0.01M as of Dec 31, 2023 |
EBITDA (TTM): | -$6.21M as of Dec 31, 2023 |
Net annual income (TTM): | -$5.13M as of Dec 31, 2023 |
Free cash flow (TTM): | -$4.18M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 139,106,226 as of Mar 11, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |